通讯作者: 赵四林, 270315298@qq.com

DOI：10.12201/bmr.202602.00043

• 摘要：特发性肺纤维化(IPF)是一种原因不明的、慢性、进行性肺间质性病变,其病理演变过程与中医肺痹至肺痿的转化高度契合。“亢害承制”理论揭示了人体在病理状态下“过亢为害”与“制约修复”之间的动态平衡关系,基于此探析特发性肺纤维化的中医病机变化,将其病程划分为肺痹亢害期、痹痿转化期及肺痿承溃期三个阶段,并系统提出“削亢”“制衡”“固本”的阶梯治疗策略:一者祛邪为主,兼以顺承；二者调燮承制,攻补兼施；三者固本救逆,维系残承。为中医辨治本病提供了新的思路。

  关键词： 特发性肺纤维化; 分期治疗; 亢害承制; 肺痹; 肺痿

   

  Abstract: (1.Hunan University of Chinese Medicine, Hunan Changsha 410208, China；2.The First Clinical Medical College of Hunan University of Chinese Medicine,Hunan Changsha 410007,China) Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown cause, and its pathological evolution highly aligns with the transformation from lung paralysis to lung wither in traditional Chinese medicine. The theory of restraining excessiveness to acquire harmony reveals the dynamic balance between the harm caused by excess and restraint and repair under pathological conditions in the human body. Based on this, the traditional Chinese medicine pathogenesis of IPF is analyzed, and its disease course is divided into three stages: the Lung Paralysis and Excess-Harm Stage, the Transition from Paralysis to Withering Stage, and the Lung Wither and Regulation-Collapse Stage. A stepwise treatment strategy of Reducing Excess, Restoring Balance, and Reinforcing the Foundation is systematically proposed: the first focuses on eliminating pathogens while facilitating regulation; the second on harmonizing restraint and repair by combining attack and tonification; and the third on consolidating the root to rescue the system and maintain residual regulatory function. This provides a new perspective for the traditional Chinese medicine diagnosis and treatment of this disease.

  Key words: idiopathic pulmonary fibrosis; restraining excessiveness to acquire harmony; staging treatment; lung paralysis; lung wither

  提交时间：2026-02-11

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 王春燕, 王其美, 贾慧彤, 祖迪, 胡栋楠. 基于“清浊升降”理论探讨特发性肺纤维化的发病机制与辨治思路. 2026. doi: 10.12201/bmr.202602.00072

  段嘉敏, 蔡旭东. 基于“亢害承制”理论探讨巨噬细胞极化在慢性肾脏病肾纤维化发展中的作用. 2024. doi: 10.12201/bmr.202407.00027

  张家芮, 杜雨芃, 林燕. 特发性腹膜后纤维化2例诊治经验探讨. 2024. doi: 10.12201/bmr.202410.00077

  孟丽红, 关炜, 薛晓明. 中药靶向肺泡上皮细胞衰老治疗肺纤维化的研究进展. 2025. doi: 10.12201/bmr.202506.00012

  成航, 凹永芳, 李琰. 基于“亢害承制”理论与铁死亡机制浅谈痛风性关节炎的病因病机及辨治. 2025. doi: 10.12201/bmr.202512.00037

  周馨蓓, 梁宁娟, 吴婷, 喻丹丹, 蒋小涵, 滕晶晶. 通过网络毒理学和分子对接策略有效探索增塑剂在肺纤维化中的毒性和分子机制：以邻苯二甲酸丁苄酯为例. 2025. doi: 10.12201/bmr.202504.00004

  李雪雪, 赵粉琴. 卵巢纤维化发生机制及相关疾病研究进展. 2025. doi: 10.12201/bmr.202501.00040

  陈薪竹, 刘承鑫, 郑爱华★. 基于“肺肠同治”理论探析生血通便颗粒治疗脓毒症急性肺损伤经验*. 2025. doi: 10.12201/bmr.202509.00041

  钱蒙蒙, 郭潇辰, 王鹏飞, 陈秀, 伍欣尧, 邹春鹏, 徐茂晟. SWE在MAFLD早期肝脏及肾脏纤维化中的应用价值. 2024. doi: 10.12201/bmr.202409.00010

  罗周青, 兰玲燕, 舒琦瑾. 从“络虚毒结”分期辨治肺癌治疗相关心悸经验. 2026. doi: 10.12201/bmr.202601.00067

• 序号	提交日期	编号	操作
  1	2026-01-28	10.12201/bmr.202602.00043V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论